What is he best known for?
The fields of study he is best known for:
- Virus
- Internal medicine
- Disease
Keith S. Reisinger mainly focuses on Immunology, Vaccination, Pediatrics, Reactogenicity and Virology.
When carried out as part of a general Immunology research project, his work on Immunogenicity, Immunization and Toxoid is frequently linked to work in Sexually transmitted disease and Genital warts, therefore connecting diverse disciplines of study.
His study on Vaccine efficacy is often connected to Placebo as part of broader study in Vaccination.
His Pediatrics study combines topics in areas such as Clinical trial, Varicella vaccine, Viral disease and Tolerability, Adverse effect.
In his research, Intensive care medicine and Oral administration is intimately related to Randomized controlled trial, which falls under the overarching field of Clinical trial.
Keith S. Reisinger focuses mostly in the field of Reactogenicity, narrowing it down to topics relating to Seroconversion and, in certain cases, Hepatitis B vaccine, Hepatitis A vaccine, Hepatitis vaccine and Twinrix.
His most cited work include:
- Oral oseltamivir treatment of influenza in children. (598 citations)
- Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. (413 citations)
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. (386 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Immunology, Vaccination, Immunogenicity, Virology and Pediatrics.
His Adverse effect research extends to the thematically linked field of Immunology.
The Vaccination study combines topics in areas such as Varicella vaccine, Internal medicine and Seroconversion.
Keith S. Reisinger interconnects Titer and Tetanus in the investigation of issues within Immunogenicity.
As a part of the same scientific family, Keith S. Reisinger mostly works in the field of Virology, focusing on Haemophilus influenzae and, on occasion, Hepatitis B.
His Pediatrics research integrates issues from Clinical trial, Viral disease, Regimen, Tolerability and Randomized controlled trial.
He most often published in these fields:
- Immunology (60.64%)
- Vaccination (53.19%)
- Immunogenicity (41.49%)
What were the highlights of his more recent work (between 2007-2019)?
- Vaccination (53.19%)
- Immunology (60.64%)
- Immunogenicity (41.49%)
In recent papers he was focusing on the following fields of study:
Keith S. Reisinger spends much of his time researching Vaccination, Immunology, Immunogenicity, Adverse effect and Pediatrics.
His Vaccination research includes themes of Internal medicine, Tolerability and Meningococcal disease.
The study of Immunology is intertwined with the study of Randomized controlled trial in a number of ways.
His Immunogenicity study integrates concerns from other disciplines, such as Titer, Antibody titer, Influenza vaccine, Adjuvant and Seroconversion.
His study in Influenza vaccine is interdisciplinary in nature, drawing from both Influenza A virus and Hemagglutination assay.
The various areas that Keith S. Reisinger examines in his Pediatrics study include Clinical trial, Milk protein, Regimen, Lactose and Disease.
Between 2007 and 2019, his most popular works were:
- Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine (91 citations)
- Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents (89 citations)
- Long-term Study of a Quadrivalent Human Papillomavirus Vaccine (83 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
